• why us?
  • Case Studies
  • Commercial development plan for a mesenchymal stem cell therapy in acute GvHD


Our client was a leading UK research institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the university. Alacrita was asked to assess the viability and market attractiveness of selected projects and to develop individual Commercial Development Plans (CDP) that could be reviewed by the funding committee. One such group requiring a CDP was developing a new mesenchymal stem cell (MSC) therapeutic for the treatment of acute graft versus host disease.


Alacrita's specialist stem cell consultant met with the Principal Investigator to collect information on all areas of the project and from this created a CDP covering the following key areas:

  • Background on the project and research team
  • Rationale of the therapeutic approach
  • Current unmet clinical need
  • Clinical differentiation of the therapy
  • Competitive landscape
  • Pathway to commercialisation
  • Development milestones
  • Budget for the project

The CDP was reviewed by the funding committee and the project was successful in achieving funding.

Contact UsReach out today for more information on our cell therapy expertise.

Related Case Studies